How to Test for Enzyme Deficiency: Methods and Results

Testing for enzyme deficiency typically starts with measuring how much work the enzyme actually does in a blood, stool, or breath sample, then confirming ambiguous results with genetic sequencing or a second type of assay. The specific method depends on which enzyme is suspected, what tissue it normally operates in, and whether the patient is a newborn, a symptomatic adult, or a relative of someone already diagnosed. No single test covers all enzyme deficiencies, but the diagnostic landscape has expanded enough that most conditions can be identified without invasive procedures.

Blood-Based Enzyme Activity Assays

The most widely used approach measures enzyme activity directly in a blood sample. A lab adds the enzyme’s natural or synthetic substrate to the sample, then measures how quickly the enzyme converts it into a product. If the rate is far below what’s expected for a healthy person, the enzyme is deficient. There are several ways to detect that product, and the choice often depends on the enzyme in question.

Spectrophotometry tracks changes in how a solution absorbs light as the enzyme reaction proceeds. For glucose-6-phosphate dehydrogenase (G6PD), a common target, the assay measures the production of NADPH, which absorbs ultraviolet light at a specific wavelength. A simpler screening version, the fluorescent spot test (FST), works on the same principle but just checks whether the blood spot glows under UV light. In neonates, the FST performs well at identifying severe deficiency, with sensitivity around 91% at a threshold of 30% normal activity. But it misses milder cases: at a 60% activity threshold, sensitivity drops to about 29%, meaning most partially deficient individuals slip through.¹ Quantitative spectrophotometric assays catch those intermediate cases, which is why many labs now use them as the primary method rather than a screen-then-confirm approach.²

Fluorometric assays use synthetic substrates that release a fluorescent tag when the enzyme cleaves them, and the brightness of the fluorescence corresponds to enzyme activity. This technique is widely used for lysosomal storage disorders like Gaucher disease, Fabry disease, and mucopolysaccharidosis II (Hunter syndrome). A validated fluorometric assay for the enzyme iduronate-2-sulfatase, for instance, allows labs to screen for Hunter syndrome from a dried blood spot and establish population-specific reference ranges.³

The Dried Blood Spot Advantage

Many of these blood-based assays now work from dried blood spots (DBS) rather than liquid blood drawn into tubes. A few drops of blood are placed on filter paper, dried, and shipped at room temperature. This makes a huge practical difference: the sample doesn’t need to be refrigerated, it’s lightweight enough for ordinary mail, and it can be collected by a finger prick rather than a venous draw. For lysosomal storage disorders in particular, DBS methods are available for a wide range of conditions and have become the backbone of both newborn screening and high-risk population screening.⁴

A large study of over 30,000 samples suspected for Pompe disease, which involves deficiency of the enzyme acid alpha-glucosidase (GAA), demonstrated that a two-step process using DBS cards works reliably across dozens of countries: first measure GAA enzyme activity, then follow up with genetic sequencing on any sample that looks abnormal biochemically. The combination catches cases that either test alone would miss.⁵ Similarly, for CLN2 disease (a form of neuronal ceroid lipofuscinosis), a fluorometric assay of the enzyme TPP1 from DBS correctly identified all 50 confirmed patients in a 12-year study, including seven with atypical presentations.⁶

Breath Tests for Digestive Enzyme Deficiencies

Not every enzyme deficiency shows up well in blood. When the missing enzyme works in the gut, breath tests offer a noninvasive way to catch the problem. The most familiar example is the lactose hydrogen breath test, used to diagnose lactase deficiency. You drink a measured dose of lactose, and if your small intestine can’t break it down, the undigested sugar passes to the colon where bacteria ferment it and produce hydrogen gas. That hydrogen is absorbed into the bloodstream and exhaled, so a rise in breath hydrogen signals malabsorption.

The standard test uses a 25-gram lactose load, which is roughly the amount in two large glasses of milk. But that dose is quite high compared to what most people consume at once, and it may overdiagnose the problem. In one study, only about 18% of patients who tested positive on the standard 25-gram dose still tested positive when retested with a more realistic 12.5-gram load, with hydrogen levels dropping dramatically.⁷ This means many people labeled as lactose malabsorbers could handle everyday portions just fine.

A refinement of the standard test adds a carbon-13-labeled substrate so the breath is measured for both hydrogen and carbon-13 carbon dioxide, giving a more complete picture of how much lactose is actually being digested. Adding methane measurement on top of that catches another group of patients entirely: about 16% of subjects with normal lactose digestion and no hydrogen excretion turn out to be methane producers, which can mask the hydrogen signal and lead to a false-negative result if only hydrogen is measured.⁸

Regional genetics also influence results. A study of healthy volunteers in India found abnormal breath test results in about 79% of southern Indians versus 57% of northern Indians, and the lactose tolerance blood test (which measures blood glucose rise after lactose) was abnormal in 88% versus 66%, respectively.⁹ These aren’t sick populations; this is the normal genetic background of lactase persistence and non-persistence across different ancestry groups, which matters when interpreting what a “positive” result actually means for a given person.

Stool Tests for Pancreatic Enzyme Deficiency

When the pancreas doesn’t produce enough digestive enzymes, a condition called exocrine pancreatic insufficiency (EPI), fats pass through undigested and the result is greasy, foul-smelling stool. The most practical initial test is measuring fecal elastase-1 (FE-1), an enzyme the pancreas secretes that survives the trip through the gut intact. You collect a single stool sample, and the lab measures elastase concentration.

At the commonly used threshold of 200 micrograms per gram of stool, a recent meta-analysis found pooled sensitivity of 94% and specificity of 69%.¹⁰ The sensitivity is reassuringly high, meaning few truly deficient patients are missed. But specificity at that cutoff is moderate, so some people without genuine EPI test positive. Dropping the threshold to 100 micrograms per gram raises specificity to about 82% while only slightly lowering sensitivity to 88%. The test performs best in certain clinical contexts: sensitivity reaches 98% in cystic fibrosis, and specificity is highest (81%) in chronic pancreatitis.

An earlier meta-analysis, comparing fecal elastase-1 against the gold-standard secretin stimulation test, found somewhat lower sensitivity at 77% but specificity of 88%. When the comparison standard was quantitative fecal fat estimation instead, sensitivity jumped to 96%.¹¹ The discrepancy reflects how different gold standards capture different aspects of pancreatic function, and it’s worth knowing that your result depends partly on what the lab is calibrating against.

After pancreatic surgery, fecal elastase-1 remains useful but may need a lower cutoff. One study found an optimal threshold of about 66 micrograms per gram (rather than the standard 200) for detecting EPI in post-surgical patients, and a carbon-13-labeled mixed triglyceride breath test performed comparably, with no significant difference in diagnostic accuracy between the two methods.¹²

Tissue Biopsy for Intestinal Enzymes

Some enzyme deficiencies are best measured directly in the tissue where they matter. Disaccharidase deficiencies, which affect the enzymes that break down double sugars like lactose, sucrose, and maltose in the intestinal lining, can be diagnosed by taking a small biopsy during an upper endoscopy and measuring enzyme activity in that tissue sample. Techniques include direct enzyme activity assays on the biopsy specimen, immunohistochemistry to visualize enzyme protein, and genetic testing for known mutations.¹³ This is more invasive than a breath test, but it’s the only way to distinguish between a primary genetic deficiency and secondary damage from conditions like celiac disease or infection, where the enzymes are low because the intestinal lining is injured rather than because the genes are faulty.

When Genetic Testing Complements Enzyme Assays

A low enzyme activity result tells you the enzyme isn’t working well, but it doesn’t always tell you why. Genetic sequencing identifies the underlying mutation, which can matter for prognosis, family planning, and whether treatment will help. In practice, the two approaches often work as a pair, each catching cases the other might miss.

Tay-Sachs disease screening illustrates the challenge. In a study of a minority population in New York City, 73 individuals had positive or inconclusive enzyme test results. All 68 unique patients were negative on standard targeted mutation panels, which were designed around mutations common in Ashkenazi Jewish populations and don’t cover variants found in other ethnic groups. Among the 12 patients who went on to full gene sequencing, only one turned out to carry a likely disease-causing mutation.¹⁴ The enzyme test cast a wide net but generated many false alarms that required expensive follow-up. In diverse populations where the known mutation panels are incomplete, enzyme assays are still the better initial screen, but they need genetic confirmation before anyone acts on the result.

The reverse problem exists too. Genetic testing alone can identify variants of unknown significance, mutations whose effect on enzyme function is unclear. To settle the question, researchers are developing large-scale functional assays that measure the consequences of thousands of variants at once, creating lookup tables of which mutations actually break the enzyme and which are benign.¹⁵ Until those databases are complete, measuring actual enzyme activity remains the most direct way to determine whether a genetic variant matters clinically.

For some enzymes, kinetic assays can even infer genotype without sequencing. The enzyme paraoxonase 1 has a common genetic variant (Q192R) that changes how it responds to salt in the assay. By measuring the ratio of activity with and without salt stimulation, one study achieved 100% correct genotype classification when combining two such ratios.¹⁶ This kind of biochemical shortcut can substitute for genetic sequencing when the polymorphism produces a clean functional signature.

Newborn Screening Programs

Newborn screening is where enzyme testing reaches its largest scale. Within the first day or two of life, a few drops of blood from a heel prick are placed on a filter paper card and shipped to a state or regional lab. Those dried blood spots are then tested for a growing list of enzyme deficiencies using tandem mass spectrometry, which can measure multiple enzyme activities from a single sample.

A multiplex assay developed for mucopolysaccharidoses and a form of neuronal ceroid lipofuscinosis measures enzyme activities using tandem mass spectrometry in a multiple-reaction-monitoring format, quantifying the products of each enzyme reaction against labeled internal standards.¹⁷ A separate multiplex platform consolidates screening for X-linked adrenoleukodystrophy, biotinidase deficiency, and galactosemia into a single injection requiring about two and a half minutes of instrument time per sample.¹⁸ The throughput matters enormously when a single lab may need to process thousands of samples a day.

A positive newborn screen is never a diagnosis by itself. It’s a flag that gets the family referred for confirmatory testing, which usually means repeating the enzyme assay on a fresh sample, running genetic sequencing, and sometimes measuring substrate or product levels in blood or urine. Newborn screening catches severe deficiencies well, but the fast turnaround and small sample size mean false positives are inevitable.

Why Your Age and Sex Change the Reference Range

Interpreting an enzyme test requires knowing what “normal” looks like for someone of your age and sex, and those ranges shift more than most people realize. A study establishing pediatric reference intervals for liver-related enzymes in healthy children found that the enzyme AST alone required seven different age-and-gender-specific partitions, from a single range at age two through separate male and female ranges in adolescence.¹⁹ All four enzymes studied needed no gender separation in early childhood but required it in later age groups, reflecting the hormonal changes of puberty.

The same pattern holds for cardiac enzymes. In a large study of healthy Chinese children and adolescents, AST declined rapidly from ages one to six and stabilized during adolescence, while lactate dehydrogenase decreased at a steadier rate. Creatine kinase activity leveled off, but its MB fraction trended downward. Sex-based differences emerged after age 12, with males showing higher levels, and age had a greater overall impact on enzyme activity than sex.²⁰ If your child’s enzyme result is compared against an adult reference range, it could look abnormally high when it’s perfectly typical for their age.

Pre-Analytical Pitfalls That Skew Results

A test is only as good as the sample that reaches the lab. Enzyme proteins can lose activity during shipping, and the conditions between sample collection and analysis matter more than many clinicians appreciate. In one dramatic case of prenatal diagnosis for succinic semialdehyde dehydrogenase (SSADH) deficiency, enzyme activity measured in chorionic villi suggested the fetus was affected, but metabolite levels in amniotic fluid were normal. The discrepancy was traced to an eight-day transit time for the tissue sample, during which the enzyme had degraded. DNA analysis confirmed the fetus was actually a carrier, not affected.²¹ The researchers concluded that combining enzyme, metabolite, and DNA analysis is essential for accuracy, especially when samples can’t be processed quickly.²²

Blood storage also affects enzyme-dependent test results. G6PD activity in stored red blood cells drops over time, and G6PD-deficient blood units show significantly faster declines in hemoglobin and red cell count over a 14-day storage period compared to normal units, with corresponding increases in cell volume markers.²³ For clinical testing, the practical takeaway is that a blood sample sitting on a bench for days before analysis may give a falsely low reading, particularly for unstable enzymes. If results don’t match the clinical picture, the lab should consider whether sample handling could be the explanation before repeating the assay.

Monitoring Treatment with Enzyme Biomarkers

Once an enzyme deficiency is diagnosed and treatment begins, usually with enzyme replacement therapy (ERT) for conditions like Fabry disease or Pompe disease, the question shifts from “is the enzyme missing?” to “is the replacement working?” Measuring enzyme activity in blood can confirm that the infused enzyme is present, but that doesn’t necessarily tell you whether it’s reaching the tissues that need it.

Biomarkers that reflect downstream damage are often more informative. In Fabry disease, where the missing enzyme allows a lipid called globotriaosylsphingosine (lyso-Gb3) to accumulate, plasma lyso-Gb3 levels serve as a treatment monitor. Classic Fabry males showed rapid drops in lyso-Gb3 after starting ERT, while later-onset males and Fabry females showed either a gradual decline or stabilization.²⁴ Even newer biomarkers are being explored: urinary myeloid bodies, microscopic structures visible under electron microscopy, showed significant reductions after one year of ERT and were specific to Fabry disease, appearing even before proteinuria developed.²⁵ Having a biomarker that moves earlier than kidney damage shows up on standard tests is valuable because it gives physicians a chance to adjust therapy before irreversible harm occurs.

Carrier Detection and X-Linked Complications

Testing for enzyme deficiency gets trickier when the goal is to identify carriers, people who have one defective copy of a gene but are usually healthy themselves. For autosomal recessive conditions, carriers typically have roughly half the normal enzyme activity. That intermediate zone overlaps with the low end of normal, making enzyme assays unreliable for carrier detection in many cases. Genetic testing is generally more definitive.

X-linked conditions introduce an extra layer of complexity. Because females have two X chromosomes and one is randomly inactivated in each cell, female carriers of an X-linked enzyme deficiency can have anywhere from near-normal to severely reduced enzyme activity depending on which X chromosome was silenced in which tissues. In Lesch-Nyhan disease, caused by deficiency of the enzyme HPRT, about 75% of carrier females show skewed X-inactivation, meaning one X chromosome is preferentially silenced across most cells. This skewing is significantly more common in carriers of the severe form of the disease (83%) than in milder variants. Using skewed X-inactivation as a diagnostic marker for carrier status gives a sensitivity of 75% and specificity of 85%.²⁶ That’s useful but far from foolproof, and it underscores why carrier testing for X-linked enzyme deficiencies often requires a combination of enzyme activity measurement, X-inactivation analysis, and molecular genetics.

Matching Enzyme Activity to Disease Severity

One question that comes up after diagnosis is whether the amount of residual enzyme activity predicts how sick someone will get. The answer depends on the condition, but the correlation often holds. A study of HPRT deficiency, which causes a spectrum ranging from gout to the severe neurological damage of Lesch-Nyhan disease, found a clear relationship between enzyme activity measured in intact cells and clinical severity.²⁷ Patients with the most severe symptoms had the least residual activity, while those with partial deficiency had milder disease. The key detail is that the measurement was done in intact fibroblasts rather than lysed cell extracts, because the way the enzyme functions inside a living cell can differ from how it behaves in a test tube. This kind of nuance matters when labs report results: a residual activity of 5% measured one way might correspond to a very different clinical outcome than 5% measured another way, depending on assay conditions.

For conditions where enzyme replacement therapy exists, this correlation also helps guide treatment decisions. A patient with residual activity of 1% is likely to benefit from earlier and more aggressive treatment than one with 15% residual activity, even though both technically have “deficiency.” Enzyme testing done under standardized conditions and interpreted alongside genetic and clinical findings gives the most complete picture of what lies ahead.